Trials / Completed
CompletedNCT03760146
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,902 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 20vPnC | 20vPnC |
| BIOLOGICAL | 13vPnC | Pneumococcal conjugate vaccine |
| BIOLOGICAL | PPSV23 | Pneumococcal polysaccharide vaccine |
| OTHER | Saline | Placebo |
Timeline
- Start date
- 2018-12-12
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
- First posted
- 2018-11-30
- Last updated
- 2021-12-02
- Results posted
- 2020-12-29
Locations
68 sites across 2 countries: United States, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03760146. Inclusion in this directory is not an endorsement.